Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
How do you manage dysgeusia from Enfortumab Vedotin?
Related Questions
Are you dose reducing/omitting IV dexamethasone as a pre-medication for anti-emesis in patients with MIBC when using durvalumab/gemcitabine/cisplatin?
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Do you plan to extrapolate from the NIAGARA trial regarding peri-operative durvalumab/cis/gem to treat upper tract urothelial carcinoma?
Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?
Are there scenarios where you would still prefer adjuvant nivolumab based on known pathologic risk over using perioperative durvalumab for patients with muscle invasive bladder cancer?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
